AUSTIN, Texas

,

Jan. 25, 2022

/PRNewswire/ — Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a Key Opinion Leader (KOL) and Patient Caregiver Webinar on Arginase 1 Deficiency on

Thursday, February 3, 2022

, at

2:30pm EST

.

The webinar will include presentations from:

• 
  Barbara Burton
  
  , M.D., Professor of Pediatrics,
  
  Northwestern University
  
  Feinberg School of Medicine, and Attending Physician in the Division of Genetics, Birth Defects and Metabolism at the Ann & Robert H. Lurie Children’s Hospital of Chicago, will provide an overview of Arginase 1 Deficiency and describe the role of arginine in the pathogenesis of the disease.

• 
  George Diaz
  
  , M.D., Ph.D., Professor of Genetics and Genomic Sciences, Icahn School of Medicine, and Director of the Program for Inherited Metabolic Diseases at
  
  Mount Sinai
  
  (
  
  New York, NY
  
  ), will discuss the enzyme therapy approach to treating patients with Arginase 1 Deficiency and clinical data.

• 
  Tanja Brandt
  
  , parent/caregiver of a 10-year-old child with Arginase 1 Deficiency, Advisor and Steering Committee Member of the Arginase 1 Deficiency Foundation (ARG1D.org), will discuss the disease burden and will provide the patient and caregiver perspective related to the challenges of living with a devastating and progressive disease.

A live question and answer session will follow the formal presentations. To register for the webinar, please click

here

. To access the live and/or archived webcast, visit the

Events & Presentations

section of the Company

‘

s website. Replays of Company webcasts are archived on the website for 30 days following presentations.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In

December 2021

, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit

Home

.

View original content to download multimedia:

https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-upcoming-kol-and-patient-caregiver-webinar-on-arginase-1-deficiency-301466577.html

SOURCE Aeglea BioTherapeutics, Inc.